Abstract
MicroRNAs (miRNAs), which are highly conserved, non-coding endogenous RNA and nearly ~22 nucleotides (nt) in length, have been widely reported to play the crucial roles in a number of pathological processes, most notably cancer. Hitherto, accumulating evidence has demonstrated that miRNAs are involved in mediating several cancer-related pathways linked to Programmed cell death (PCD), indicating that miRNAs may function as the key regulators in apoptosis and autophagy of cancer. In this review, we present a brief outline of the discovery, biosynthetic pathway and regulatory mechanisms of miRNAs, and further elucidate how miRNAs can regulate apoptotic and autophagic pathways as oncogenes or tumor suppressor genes in cancer. Together, these inspiring findings would help cancer biologists and clinicians uncover the mysterious landscape of miRNAs, thereby ultimately harnessing the miRNA-targeted PCD pathways for future cancer therapeutics.
Keywords: Apoptosis, autophagy, cancer, MicroRNA (miRNA), Programmed Cell Death (PCD)
Current Chemical Biology
Title:MicroRNA Regulation of Programmed Cell Death Pathways in Cancer
Volume: 6 Issue: 1
Author(s): Miao Ming, Xu Zhao, Zi-yi Zhao, Bo Liu and Jin-ku Bao
Affiliation:
Keywords: Apoptosis, autophagy, cancer, MicroRNA (miRNA), Programmed Cell Death (PCD)
Abstract: MicroRNAs (miRNAs), which are highly conserved, non-coding endogenous RNA and nearly ~22 nucleotides (nt) in length, have been widely reported to play the crucial roles in a number of pathological processes, most notably cancer. Hitherto, accumulating evidence has demonstrated that miRNAs are involved in mediating several cancer-related pathways linked to Programmed cell death (PCD), indicating that miRNAs may function as the key regulators in apoptosis and autophagy of cancer. In this review, we present a brief outline of the discovery, biosynthetic pathway and regulatory mechanisms of miRNAs, and further elucidate how miRNAs can regulate apoptotic and autophagic pathways as oncogenes or tumor suppressor genes in cancer. Together, these inspiring findings would help cancer biologists and clinicians uncover the mysterious landscape of miRNAs, thereby ultimately harnessing the miRNA-targeted PCD pathways for future cancer therapeutics.
Export Options
About this article
Cite this article as:
Ming Miao, Zhao Xu, Zhao Zi-yi, Liu Bo and Bao Jin-ku, MicroRNA Regulation of Programmed Cell Death Pathways in Cancer, Current Chemical Biology 2012; 6 (1) . https://dx.doi.org/10.2174/2212796811206010053
DOI https://dx.doi.org/10.2174/2212796811206010053 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Insects Antiviral and Anticancer Peptides: New Leads for the Future?
Protein & Peptide Letters Medical Chemistry to Spy Cancer Stem Cells from Outside the Body
Mini-Reviews in Medicinal Chemistry The Use of the Zebrafish Model to Aid in Drug Discovery and Target Validation
Current Topics in Medicinal Chemistry Overview: Translating Hsp90 Biology into Hsp90 Drugs
Current Cancer Drug Targets Is the Expression of Deoxynucleoside Kinases and 5'-nucleotidases in Animal Tissues Related to the Biological Effects of Nucleoside Analogs?
Current Medicinal Chemistry Progress in the Development of Selective Inhibitors of Aurora Kinases
Current Topics in Medicinal Chemistry H3K4 Methylation Status and Lysine Specific Methyltransferase KMT2C Expression Correlate with Prognosis in Lung Adenocarcinoma
Current Molecular Pharmacology Molecular Targeting of Aberrant Transcription Factors in Leukemia: Strategies for RUNX1/ETO
Current Drug Targets Appreciating the Balance between Classical Interleukin (IL)-6 Receptor Signaling and IL-6 Trans-Signaling: Implications for Arthritis Progression
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Severe Hypoglycemia Due to Possible Interaction Between Glibenclamide and Sorafenib in a Patient with Hepatocellular Carcinoma
Current Drug Safety The Shape of the Messenger: Using Protein Structure Information to Design Novel Cytokine-based Therapeutics
Current Pharmaceutical Design Development of DNA Topoisomerase II-Mediated Anticancer Agents, 3-(9- Acridinylamino)-5-hydroxymethylanilines (AHMAs) and Related Compounds
Current Medicinal Chemistry The Function and Regulation of BMP6 in Various Kinds of Stem Cells
Current Pharmaceutical Design The Functions of Polo-Like Kinases and their Relevance to Human Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects
Current Pharmaceutical Design Editorial [Hot Topic: Oncohematology: From Bench to Bedside (Guest Editor: Vincenzo De Feo)]
Mini-Reviews in Medicinal Chemistry New and Highly Potent Antitumor Natural Products from Marine-Derived Fungi: Covering the Period from 2003 to 2012
Current Topics in Medicinal Chemistry Improving Safety of Gene Therapy
Current Drug Safety Protein Microarrays: Technological Aspects, Applications and Intellectual Property
Recent Patents on Biotechnology Naturally Occuring Pyrrolo[1,4]benzodiazepines in Bacteria
Mini-Reviews in Organic Chemistry